Overview

Safety and Efficacy Study of Oral Fispemifene for the Treatment of Sexual Dysfunction in Hypogonadal Men

Status:
Unknown status
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety and efficacy of fispemifene in men with secondary hypogonadism and sexual side effects.
Phase:
Phase 2
Details
Lead Sponsor:
NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.)
Treatments:
Tamoxifen